BIOA

XNAS

BioAge Labs, Inc.

Mkt Cap $738MPHARMACEUTICAL PREPARATIONS

FUNDAMENTALS

P/S

98.16

EV/EBITDA

-7.61

P/B

2.67

EPS (TTM)

$-2.02

ROE

-23.7%

ROA

-22.6%

FCF

$-88.6M

MKT CAP

$1.0B

AI PREDICTION · 3-MONTH VIEW

▲Edge over the market

BIOA holds a similar standing over 1 and 3 months.

WHERE IT RANKS · vs 2,129 names

20-DAY

▲#26

60-DAY

▲Top 15%#315

TYPICAL 3-MO RANGE · vs S&P 500

+0.1%leans upper+1.1%

▸ Horizon detail

20d#26

60dTop 15%

1y+analyst mean$43.73+92.7%

⚡ AI INSIGHT

Our model reads BIOA as strong both near-term and over the next few months. Analysts agree (80% Buy) — the bull case lines up.

RECENT CATALYSTS

NEWSPhase 2 trial initiation for BGE-10229d
ANALYST_ACTIONSRoth Capital init coverage Buy49d
ANALYST_ACTIONSBTIG init coverage Buy53d
NEWSPresenting at Upcoming Investor Conferences54d
NEWSPhase 2 trial planned for BGE-10256d

REVENUE & GROWTH

$3M

Revenue

-0.1%

QoQ

+0.9%

YoY

Gross Margin

1.0%Stable

SHORT & FLOAT

Free Float

70.9%

4.0 days to cover.

Latest Headlines

BioAge Labs: Developing A 'Pipeline In A Pill'

SeekingAlpha6/24/2026

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

GlobeNewswire Inc.6/16/2026

BioAge Labs Doses First Participant Dosed In QUELL-CV

Benzinga6/16/2026